To date, the clinical blood tumor biomarkers are limited, including alpha-fetoprotein (AFP), cancer antigen 19-9 (CA19-9), and carcinoembryonic antigen (CEA), all of which demonstrate low sensitivity. Here, AFP is linked to neoplasm.